In this episode, Linda R. Duska, MD, MPH; Robert L. Coleman, MD, FACOG, FACS; and Leslie Randall, MD, MAS, answer questions from an audience of healthcare professionals on topics related to the management of patients with endometrial and ovarian cancer including: Adding bevacizumab to chemotherapy in frontline endometrial cancerLenvatinib and pembrolizumab in MSI-H/dMMR endometrial cancerPARP inhibitor maintenance in ovarian cancerBevacizumab with or without PARP inhibitors in ovarian cancerPresenters:Linda R. Duska, MD, MPHLawrence W. Penniston MD Family Professor in Women’s Oncology ResearchDivision of Gynecologic OncologyDepartment of Obstetrics and GynecologyUniversity of Virginia School of MedicineCharlottesville, VirginiaRobert L. Coleman, MD, FACOG, FACSGynecologic Oncologist and Chief Scientific OfficerUS Oncology, US Oncology ResearchThe Woodlands, TexasLeslie Randall, MD, MAS Diane Harris Wright Professor and DirectorDivision of Gynecologic OncologyDepartment of Obstetrics and GynecologyMassey Cancer CenterVirginia Commonwealth UniversityRichmond, VirginiaLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:https://bit.ly/3e6pZCM

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related